Next results · Q4 2026Projected
Feb 23, after the close
Tue, Feb 23, 2027in 98 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 24 – Mar 19
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $23.80M
- Revenue, change from a year earlier: Q3 2026 −0.9%, Q2 2026 −7.6%, Q1 2026 +4.6%, Q4 2025 +2,573.6%
- Net income
- $19.28M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 3.9% either way
Up after 6 of 12, down after 6.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −29.0% after Q2 2024.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Varies
- Session
- after the close
- After quarter end
- 35 to 55 days
- 10-Q filed
- 35 to 37 days
- over its last 8
- 10-K filed
- 58 to 75 days
- over its last 8
Based on 8 prior 10-K filings.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR